Related Experiment Video

Updated: Aug 10, 2026

Cell-free Biochemical Fluorometric Enzymatic Assay for High-throughput Measurement of Lipid Peroxidation in High Density Lipoprotein
07:29

Cell-free Biochemical Fluorometric Enzymatic Assay for High-throughput Measurement of Lipid Peroxidation in High Density Lipoprotein

Published on: October 12, 2017

[The importance of lipoprotein(a) in pathogenesis of the high risk unstable angina]

Mustafa Yazici1, Sabri Demircan, Firdovsi Ibrahimli

  • 1Ondokuz Mayis Universitesi Tip Fakültesi, Kardiyoloji Anabilim Dali, Kurupelit 55139 - Samsun-Türkiye. drmeyaz@hotmail.com

Anadolu Kardiyoloji Dergisi : AKD = the Anatolian Journal of Cardiology
|March 10, 2006
PubMed

Insights

Elevated lipoprotein (a) [Lp(a)] levels correlate with higher cardiac troponin-I (cTn-I) in unstable angina patients. This suggests Lp(a) may indicate plaque instability and myocardial injury.

Area of Science:

  • Cardiology
  • Biochemistry
  • Clinical Medicine

Background:

  • Unstable angina pectoris is a critical cardiovascular condition.
  • Lipoprotein (a) [Lp(a)] is an emerging biomarker in cardiovascular disease.
  • Cardiac troponin-I (cTn-I) is a key indicator of myocardial damage.

Purpose of the Study:

  • To compare Lp(a) levels in patients with low versus high-risk unstable angina, stratified by cTn-I levels.
  • To investigate the relationship between Lp(a) and myocardial damage in unstable angina.
  • To explore the association of Lp(a) with coronary artery disease severity.

Main Methods:

  • Blood samples were collected from chest pain patients for Lp(a), C-reactive protein (CRP), and cTn-I measurements.
  • Patients were categorized into negative (cTn-I <1.0 ng/ml) and positive (cTn-I ≥1.0 ng/ml) unstable angina groups.
  • Coronary artery disease severity was assessed using angiography.

Main Results:

  • Lp(a) levels were significantly higher in the cTn-I positive group compared to the negative group (52.9±6.0 mg/dl vs 15.7±2.5 mg/dl, p<0.0001).
  • A significant positive correlation was observed between Lp(a) and cTn-I levels (r=0.870, p=0.0001).
  • No significant correlation was found between Lp(a) and Gensini score or between Lp(a) and multi-vessel disease.

Conclusions:

  • Elevated Lp(a) levels in high-risk unstable angina patients are linked to myocardial injury.
  • Lp(a) may serve as a risk factor for plaque destabilization and thrombosis in unstable angina.
  • Lp(a) appears more related to plaque instability than to the severity of coronary artery disease in this context.
Abstract

Related Concept Videos

Atherosclerosis I: Introduction01:30

Atherosclerosis I: Introduction

Atherosclerosis is a progressive disorder characterized by the buildup of plaques on the arterial inner wall, causing them to narrow and harden over time. These plaques comprise lipids, calcium, blood components, carbohydrates, and fibrous tissue. The process primarily affects the intima of large and medium-sized arteries, reducing blood flow in any artery.Etiology and risk factorsThe cause of atherosclerosis is multifactorial, involving a complex interplay among endothelial injury, lipid...
Angina IV: Management01:26

Angina IV: Management

IntroductionThe management of angina requires a comprehensive approach that includes pharmacological therapies, medical procedures, and lifestyle modifications.Pharmacological TherapiesAntiplatelet agents, such as aspirin, clopidogrel, prasugrel, and ticagrelor, play a pivotal role in preventing thrombus formation in patients with angina. These medications inhibit platelet aggregation and reduce the likelihood of myocardial infarction and other cardiovascular events.Anticoagulants, including...
Atherosclerosis III: Management01:26

Atherosclerosis III: Management

Management of atherosclerosis involves an integrated strategy encompassing pharmacological treatment, surgical interventions, lifestyle changes, and nutrition therapy to address the multifactorial nature of the disease.Pharmacological TherapyA cornerstone of atherosclerosis management is the use of pharmacological agents. Statins, such as atorvastatin, are pivotal in inhibiting HMG-CoA reductase, an enzyme that catalyzes an initial step in cholesterol synthesis in the liver. This reduction in...
Coronary Artery Disease II: Pathophysiology01:26

Coronary Artery Disease II: Pathophysiology

Coronary Artery Disease (CAD) originates from a series of events that impair the function of coronary arteries, the blood vessels responsible for delivering oxygen-rich blood to the heart muscle. The pathophysiology of CAD is closely linked to atherosclerosis, a chronic inflammatory and lipid-driven condition affecting the vascular endothelium.1. Endothelial DamageThe process begins with damage to the vascular endothelium, which serves as a protective barrier between the blood and the vessel...
Lipid-derived Compounds in the Human Body01:31

Lipid-derived Compounds in the Human Body

Fats and lipids are crucial components in the human body. Some lipid-derived compounds, such as fat-soluble vitamins, eicosanoids, lipoproteins, and glycolipids, also play unique roles to support various  biological processes .
Fat-soluble Vitamins
Fat-soluble vitamins, including vitamins A, D, E, and K, are required in minimal quantities, but their deficiencies can lead to severely abnormal physiological conditions. For example, vitamin A deficiency can cause night blindness, dry skin, delayed...
Overview of Lipid Metabolism01:24

Overview of Lipid Metabolism

Lipid metabolism is a crucial process in the human body that involves the synthesis and degradation of lipids. This process is essential for energy production, cell membrane formation, and hormone production, among other functions.
Lipolysis: The Breakdown of Lipids:
Lipolysis is the process of breaking down lipids, particularly triglycerides, into glycerol and fatty acids. This process typically occurs in the adipose tissue and is triggered by various hormones, including glucagon and...